Loading asset research
Entrada Therapeutics Inc. Common Stock
TRDANasdaq · USD · StocksQuote as of · Exchange session not verified$6.81
+6.07%
Today
TRDA
Loading 1D prices…
Market cap
$264.8M
Volume
291.8K
52w high
$16.4552w low
$5.02Company profile
Entrada Therapeutics Inc. Common Stock
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Boston, MA, United States
Employees
152
Fiscal year end
1231
CIK
1689375
Session & valuation
Open$6.49
Previous close$6.42
Day high$6.81
Day low$6.29
30-day avg. volume319.5K
Outstanding shares38.9M
Diluted EPS-$3.47
Latest annual period
P/E (trailing)-1.96
P/E (forward)-2.26
Price / book0.90
Beta-0.25
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| AKBAAkebia Therapeutics Inc. Common Stock | $263.7M | $236.2M | -2.24% | -$0.02 | +0.84% | Buy |
| CAMPCAMP4 Therapeutics Corporation Common Stock | $266.7M | $3.5M | -2298.54% | -$2.65 | -1.61% | Buy |
| FHTXFoghorn Therapeutics Inc. Common Stock | $262.5M | $30.9M | -240.33% | -$1.18 | -1.89% | Buy |
| PRQRProQR Therapeutics N.V. Ordinary Shares | $262.5M | — | — | -$0.40 | -3.61% | Buy |
| PYXSPyxis Oncology Inc. Common Stock | $267.7M | $13.9M | -574.55% | -$1.28 | -1.83% | Buy |